Results 71 to 80 of about 67,402 (252)

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. [PDF]

open access: yes, 2017
Purpose: Pazopanib, a multireceptor tyrosine kinase inhibitor targeting primarily VEGFRs1–3, is approved for advanced soft tissue sarcoma (STS) and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK inhibitor used for melanoma.
Azad, Nilofe A.   +10 more
core   +1 more source

Skull Base Surgery in the Pediatric Population—The 2nd International Collaborative Study (1995–2015)

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The current study presents the efforts of a global collaborative group to review the management and outcomes of malignant tumors of the skull base in the pediatric population worldwide. Patients and Methods A total of 28 institutions contributed data on 3061 patients. From this, there were 64 pediatric patients (2.1%).
Dan M. Fliss   +50 more
wiley   +1 more source

Rhabdomyosarcoma-Induced Uterine Inversion

open access: yesCase Reports in Obstetrics and Gynecology, 2022
Nonpuerperal uterine inversion is a rare clinical condition that involves prolapse of the uterine fundus into the uterine cavity and vaginal vault and possibly passed the introitus.
Kin Li   +3 more
doaj   +1 more source

CRISPR‐Cas9 Genome‐Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He   +2 more
wiley   +1 more source

Proton beam therapy for a patient with prostatic rhabdomyosarcoma: a case report and review of the literature

open access: yesFrontiers in Oncology
Rhabdomyosarcoma (RMS) is a malignant tumor that is more common in children and rarely occurs in adults. Its prognosis mainly depends on the tumor stage and genetic type.
Wencui Yang   +5 more
doaj   +1 more source

Embryonal Rhabdomyosarcoma of the Mandible

open access: yesPhilippine Journal of Otolaryngology Head and Neck Surgery, 2005
Objectives: 1] To describe a case of an embryonal rhabdomyosarcoma presenting as a radiolucent mandibular mass in a 3-year-old child. 2] To review existing literature on the clinical picture and pathophysiology of intraosseous rhabdomyosarcoma.
Rodante A. Roldan   +2 more
doaj   +1 more source

The role of midfacial degloving in modern rhinological practice [PDF]

open access: yes, 1999
The midfacial degloving approach has been available for twenty five years and is slowly increasing in popularity in the management of extensive benign lesions of the sinonasal region, for selected malignancy in this area and to afford access to the ...
Howard, DJ, Lund, VJ
core   +1 more source

Development and validation of a nutrition risk screening for patients with childhood cancer in Brazil (NUTRICCAN)

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background Diagnosing malnutrition in patients with pediatric cancer is challenging because tumor masses can interfere with anthropometric measurements. STRONGkids considers cancer a general risk factor, whereas Screening Tool for Childhood Cancer (SCAN) classifies patients as at risk or not, potentially missing those who need nutrition ...
Cristiane Ferreira Marçon   +2 more
wiley   +1 more source

Primary Conjunctival Embryonal Rhabdomyosarcoma in an 8-Year-Old Girl

open access: yesCase Reports in Ophthalmology
Introduction: Rhabdomyosarcoma is a rare paediatric cancer, with the head and neck region representing a major anatomical site for rhabdomyosarcoma. In particular, orbital rhabdomyosarcoma is the most common region among children.
Shima Bakhtiary, Michael Barkley
doaj   +1 more source

Cyclin D1 as a Useful Marker for the Differentiation of Ewing’s Sarcoma from Rhabdomyosarcoma

open access: yesMiddle East Journal of Cancer, 2020
Background: The main oncogenic action of CD99 and cyclin D1 biomarkers is referred to any mutation, amplification, and overexpression in cyclin D1 coding gene, altering cell cycle progression as the main mechanism observed in a variety of tumors.
Tina Shooshtarizadeh   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy